CAS 1009119-65-6

Daclatasvir dihydrochloride

Description:

Daclatasvir dihydrochloride is an antiviral medication primarily used in the treatment of hepatitis C virus (HCV) infections. It functions as a direct-acting antiviral agent, specifically an NS5A inhibitor, which interferes with the viral replication process. The substance is characterized by its white to off-white crystalline powder form and is soluble in water, making it suitable for formulation in various dosage forms. Daclatasvir dihydrochloride has a molecular formula that reflects its complex structure, which includes multiple functional groups that contribute to its pharmacological activity. The compound is typically administered in combination with other antiviral agents to enhance efficacy and reduce the likelihood of resistance development. Its pharmacokinetics indicate a relatively long half-life, allowing for once-daily dosing in clinical settings. As with many medications, potential side effects may include fatigue, headache, and gastrointestinal disturbances, necessitating careful monitoring during treatment. Overall, Daclatasvir dihydrochloride represents a significant advancement in the management of hepatitis C, contributing to improved cure rates in affected populations.

Formula: C₄₀H₅₀N₈O₆·2ClH

InChI: InChI=1S/C40H50N8O6.2ClH/c1-23(2)33(45-39(51)53-5)37(49)47-19-7-9-31(47)35-41-21-29(43-35)27-15-11-25(12-16-27)26-13-17-28(18-14-26)30-22-42-36(44-30)32-10-8-20-48(32)38(50)34(24(3)4)46-40(52)54-6;;/h11-18,21-24,31-34H,7-10,19-20H2,1-6H3,(H,41,43)(H,42,44)(H,45,51)(H,46,52);2*1H/t31-,32-,33-,34-;;/m0../s1

InChI key: InChIKey=BVZLLUDATICXCI-JMSCDMLISA-N

SMILES: C([C@@H](NC(OC)=O)C(C)C)(=O)N1[C@@H](CCC1)C=2NC(=CN2)C3=CC=C(C=C3)C4=CC=C(C=C4)C=5NC(=NC5)[C@H]6N(C([C@@H](NC(OC)=O)C(C)C)=O)CCC6.Cl

Synonyms:

• Bms 790052-05
• Carbamic acid, N,N′-[[1,1′-biphenyl]-4,4′-diylbis[1H-imidazole-5,2-diyl-(2S)-2,1-pyrrolidinediyl[(1S)-1-(1-methylethyl)-2-oxo-2,1-ethanediyl]]]bis-, C,C′-dimethyl ester, hydrochloride (1:2)
• Daclatasvir dihydrochloride
• Daclatasvir.2HCL
• Daklinza
• N,N'-[[1,1'-Biphenyl]-4,4'-diylbis[1H-imidazole-5,2-diyl-(2S)-2,1-pyrrolidinediyl[(1S)-1-(1-methylethyl)-2-oxo-2,1-ethanediyl]]]biscarbamic acid dimethyl ester hydrochloride

Carbamic acid, N,N'-[[1,1'-biphenyl]-4,4'-diylbis[1H-imidazole-5,2-diyl-(2S)-2,1-pyrrolidinediyl[(1S)-1-(1-methylethyl)-2-oxo-2,1-ethanediyl]]]bis-, C,C'-dimethyl ester, hydrochloride (1:2)

CAS: 1009119-65-6

Formula: C₄₀H₅₁ClN₈O₆

Purity: %

Color and Shape: Solid

Molecular weight: 775.3359

Ref: IN-DA00036J

Daclatasvir Dihydrochloride

CAS: 1009119-65-6

Daclatasvir Dihydrochloride

Purity: 98%

Molecular weight: 811.8g/mol

Ref: 54-OR1029031

Daclatasvir DiHCl

CAS: 1009119-65-6

Formula: C₄₀H₅₀N₈O₆·2HCl

Color and Shape: Pink Solid

Molecular weight: 738.89 2*36.46

Ref: 4Z-D-145001

Daclatasvir dihydrochloride

CAS: 1009119-65-6

Daclatasvir dihydrochloride

Purity: ≥98%

Molecular weight: 811.8g/mol

Ref: 54-BUP11912

Daclatasvir dihydrochloride

CAS: 1009119-65-6

Daclatasvir dihydrochloride is an oral antiviral that treats chronic hepatitis C by inhibiting HCV's NS5A; rare liver enzyme elevation, seldom causes jaundice.

Formula: C₄₀H₅₂Cl₂N₈O₆

Purity: 99.67%

Color and Shape: Solid

Molecular weight: 811.8

Ref: TM-T1786

Daclatasvir Dihydrochloride

Controlled Product

CAS: 1009119-65-6

Applications Daclatasvir Dihydrochloride is an anti-hepatitis C drug.
References Song, B., et. al.: Zhongguo Xinyao Zazhi, 22, 2679 (2013); Gao, M., et al.: Nature, 465(7294), 96 (2010); Bell, T. W., Chem. Med. Chem., 5(10), 1663 (2010);

Formula: C₄₀H₅₀N₈O₆·2HCl

Color and Shape: Neat

Molecular weight: 811.8

Ref: TR-D101505

Daclatasvir Dihydrochloride

CAS: 1009119-65-6

Formula: C₄₀H₅₀N₈O₆(HCl)

Molecular weight: 738.9 : 2(36.46)

Ref: ST-EA-CP-D71007

Daclatasvir dihydrochloride

CAS: 1009119-65-6

Daclatasvir is a direct-acting antiviral agent that inhibits the activity of the NS5A protein, which is a nonstructural protein required for viral replication. It has been shown to be active against hepatitis C virus (HCV) genotype 1b and genotype 2a and also has synergistic activity with other antiviral agents. Daclatasvir has been shown to have significant cytotoxicity against cells in culture. The drug may interact with some drugs and can affect the pharmacokinetics of other drugs. Daclatasvir is metabolized by cytochrome P450 enzymes, which could lead to drug-drug interactions. Daclatasvir is a substrate for polymerase chain reaction amplification methods, such as real-time PCR, limiting its use as a diagnostic tool.

Formula: C₄₀H₅₀N₈O₆·2HCl

Purity: Min. 95%

Color and Shape: White Powder

Molecular weight: 811.8 g/mol

Ref: 3D-FD46516